桦褐孔菌不同提取成分对小鼠免疫功能比较研究

采用正交水提醇沉淀法提取桦褐孔菌成分,得出其最佳提取方法。采用腹腔巨噬细胞吞噬法、测量小鼠免疫器官质量法和测定老龄大鼠SOD酶的活性,研究其对正常小鼠免疫功能的影响及对老龄大鼠抗氧化能力。与乙醇回流提取法和索氏提取法生理盐水组进行比较,得出桦褐孔菌成分可显著提高正常小鼠腹腔巨噬细胞的吞噬功能。通过比较,水提法得到的桦褐孔菌有效成分提高免疫力的作用最强,也证明了桦褐孔菌多糖能通过提高超氧化物歧化酶活性增强老龄大鼠机体的抗氧化能力。     

假单胞菌菌苗免疫调节和抑瘤活性的实验研究

应用假单胞菌菌苗(DLPV)皮下注射来调节荷瘤小鼠的免疫功能.结果发现DLPV能解除小鼠荷瘤状态所抑制的自然杀伤细胞的细胞毒活性以及脾脏单个核细胞的增殖活力;同时发现,DLPV能够显著提高荷瘤小鼠腹腔巨噬细胞的细胞毒活性.其结果,经DLPV治疗的荷瘤小鼠,其体内的移植瘤的生长受到明显抑制(肿瘤生长抑制率达到41.35%).通过测定血清和瘤体中谷胱甘肽-硫转移酶(GST)和γ-谷氨酰转移酶(γGT)的活性,也证实了DLPV的抑制作用.     

蛋白质粉对小鼠免疫功能的影响

目的探讨蛋白质粉对正常小鼠免疫调节作用。方法将BALB/c小鼠随机分为3批,每批分为4组,分别进行了小鼠免疫器官/体质量比值测定和小鼠碳廓清实验;绵羊红细胞诱导小鼠DTH、抗体生成细胞检测和血清凝血素测定（HC50）;ConA诱导的小鼠脾淋巴细胞转化实验和乳酸锂脱氢酶法（LDH）测定NK细胞活性;小鼠腹腔巨噬细胞吞噬鸡红细胞实验。结果10.00 g/kg剂量的蛋白质粉可增强绵羊红细胞诱导小鼠DTH能力（P〈0.05）,促进抗体生成细胞数的生成（P〈0.01）。3.33 g/kg和10.00 g/kg剂量组能促进ConA诱导的小鼠脾淋巴细胞转化能力（P〈0.05或P〈0.01）和血清凝血素的生成（P〈0.05）;三个剂量组均能提高小鼠腹腔巨噬细胞吞噬鸡红细胞能力（P〈0.05或P〈0.01）;3.33 g/kg和10.00 g/kg剂量组能提高NK细胞活性（P〈0.05）;但对小鼠碳廓清能力和免疫器官/体重比值无明显影响。结论蛋白质粉对正常小鼠的细胞、体液免疫和单核-巨噬细胞功能和NK功能有促进作用,即具有增强免疫力功能。     

兔小囊肽对免疫功能低下小鼠的免疫调节作用

通过腹腔注射地塞米松(DEX)建立小鼠免疫低下模型,探讨兔小囊肽(RSRP)对正常小鼠和免疫低下小鼠的免疫调节作用.采用碳廓清实验、MTT法和流式细胞分析等方法检测小鼠巨噬细胞吞噬功能、脾脏T、B淋巴细胞的增殖以及T细胞亚群.实验结果表明RSRP可以显著提高免疫低下小鼠的脾脏指数(p＜0.01);提高免疫低下小鼠的碳廓清指数k和吞噬指数a(p＜0.01);RSRP还明显拮抗DEX对脾脏T、B淋巴细胞增殖的抑制作用,提高CD4 、CD8 细胞数量,使CD4 、CD8 细胞比值上升(p＜0.01);RSRP对正常小鼠的各项免疫指标也具有一定的促进作用.由此可以看出,RSRP可以明显改善免疫低下小鼠的先天性免疫和获得性免疫功能,具有良好的免疫增强作用.     

红色诺卡氏菌的生物活性

为了考察红色诺卡氏菌菌体(NC)的生物活性, 通过一定浓度的NC对小鼠灌胃给药, 检测其毒性及对免疫器官、巨噬细胞(MΦ)吞噬功能的影响和对肉瘤S180抑制作用。结果表明小鼠口服NC, LD50>10 g/kg; NC明显增加小鼠胸腺脾脏重量、提升白细胞数量和提高小鼠MΦ的吞噬活性; 对小鼠腹腔MΦ具有明显的激活作用, 激活了的MΦ能增强抑杀白色念珠菌作用, 正常的小鼠MΦ也有一定的杀菌作用, 两者差异显著; 对小鼠S180腹水型转实体瘤具有明显的抑制作用。由此得出的结论是, NC毒性低, 能显著增强机体     

细虫草胞外多糖对小鼠腹腔巨噬细胞免疫功能研究

本实验在体外条件下,以人工发酵培养的细虫草胞外多糖OgE、OgE-F1和OgE-F2作用于小鼠腹腔巨噬细胞RAW264.7,通过测定其对巨噬细胞的增殖率、代谢MTT活力、NO分泌和吞噬能力的影响,评价细虫草胞外多糖的免疫调节活性。结果表明,细虫草多糖对巨噬细胞无细胞毒性,且能促进巨噬细胞代谢MTT活力;在0.2mg/mL^1.0mg/mL浓度范围内,多糖呈剂量依赖性的促进巨噬细胞分泌NO水平和吞噬能力。本研究表明,细虫草多糖能有效地增强小鼠巨噬细胞的活性,潜在地可改善小鼠的先天性免疫调节。     

双歧杆菌发酵果蔬汁对小鼠免疫功能的影响

目的研究双歧杆菌发酵果蔬汁对小鼠免疫功能的影响。方法将小鼠随机分成纯净水对照组与发酵果蔬汁低、中和高3个剂量组,饮水法喂饲小鼠,测定小鼠胸腺和脾脏指数、腹腔巨噬细胞吞噬功能、血清溶血素测定、皮肤迟发型超敏反应(DTH)程度。结果与对照组比较,3种果蔬汁能显著增强巨噬细胞吞噬功能,增加血清溶血素抗体水平和DTH程度。结论双歧杆菌发酵果蔬汁能提高机体的免疫功能。     

灵芝孢子粉免疫调节作用研究

观察DNFB诱导小鼠迟发型变态反应、血清溶血素测定（血凝法）、小鼠腹腔巨噬细胞吞噬鸡红细胞试验,结果表明,灵芝了粉可以促进小鼠细胞免疫功能提高体液免疫功能,促进小鼠体内抗体的产生,具有增强小鼠腹腔巨噬细胞吞噬功能,是一种比较有效的免疫调节剂。     

小麦肽对受环磷酰胺免疫抑制小鼠的免疫调节及抗氧化功能

本研究旨在分析小麦蛋白活性肽对免疫抑制小鼠免疫功能和抗氧化功能的调节作用。小鼠灌胃小麦肽10d,第8天用环磷酰胺诱导免疫抑制,测定血清溶血素、抗体生成细胞含量、脾细胞增殖、体外腹腔巨噬细胞吞噬能力、肝脏抗氧化酶活性和丙二醛(MDA)含量以及血清清除DPPH和·OH的能力。实验结果表明,环磷酰胺处理显著的降低了小鼠血清中抗SRBC抗体(溶血素HC50)水平和腹腔巨噬细胞的吞噬能力;同时伴随着肝脏超氧化物歧化酶活性(SOD)、过氧化氢酶活力(CAT)、总抗氧化能力(T-AOC)的降低和MDA含量的提高。给小鼠灌胃小麦肽可以恢复HC50和脾细胞增殖,显著提高抗体生成细胞含量和腹腔巨噬细胞吞噬能力;此外,小麦肽增强了小鼠血清清除DPPH和清除·OH的能力。以上结果表明,小麦肽可以调节应激状态引起的机体抗氧化体系紊乱及免疫功能的降低。这可能与小麦肽缓冲自由基生成、激活腹腔巨噬细胞和脾淋巴细胞活性有关。     

丙酸杆菌细胞壁骨架对小鼠乳腺癌的抑瘤作用

丙酸杆菌细胞壁骨架(Propionibacterium Cell Wall Skeleton, P-CWS)是从非致病性的丙酸杆菌中提取的乳浊状制剂。本文研究了P—CWS对小鼠乳腺癌的抑瘤作用及免疫机制。实验表明,体内给予P—CWS能活化小鼠脾脏非粘附细胞,在过继抗癌免疫试验中能抑制肿瘤的发生和发展。带瘤小鼠体内给予P—CWS能抑制肿瘤生长,改善带瘤小鼠脾脏NK、ADCC活性和腹腔巨噬细胞产生白细胞介素—1(IL—1)的能力。在体外P—CWS与脾细胞共同培养一定的时间,可提高其NK和ADCC活性;适量P—CWS与腹腔巨噬细胞共同培养48hr,能诱导巨噬细胞分泌IL—1。结果提示P—CWS具有抑瘤作用,其抑瘤效应与NK、ADCC活性增强以及腹腔巨噬细胞活化有关。P—CWS是一种有潜力的生物学反应修饰剂。     

Clearance and killing of Candida albicans in the perfused mouse liver

Hepatic interactions of C. albicans with perfused mouse livers were characterized and compared in normal and glucan-treated mice. Normal livers, in the absence of serum, trapped greater than 90% and killed greater than 20% of the infused yeast. Phenylbutazone had no effect. Silica treatment abolished killing and decreased trapping suggesting that candidicidal activity of the liver is mediated by Kupffer cells. Immune serum, but not normal serum, enhanced trapping and killing in normal livers. Liver hypertrophy was evident in mice treated with glucan, but no enhanced candidicidal activity was observed in the absence of humoral factors. Specific immune serum and normal serum increased killing of C. albicans in glucan stimulated livers, suggesting a requirement for serum opsonin in facilitating glucan enhanced killing. Specific immune serum potentiated the greatest increase in killing. Glucan treatment in conjunction with immune serum increased killing to approximately 40%. D-mannose, but not D-glucose or D-mannitol impaired trapping of the yeast in livers of normal mice. Together, the data suggest that hepatic trapping of C. albicans involves phagocytic events as well as interactions of the yeast with surface receptors on sinusoidal cells and support the role for the liver in restricting hematogenous dissemination of C. albicans in the infected host.     

Studies on the interactions of immunostimulated macrophages and Yersinia enterocolitica O:8

Immunological and electron microscopy investigations of the phagocytic and killing activities of peritoneal macrophages from rats and mice against Yersinia enterocolitica serotype O:8 cells were performed. The effect of in vivo application of cytoplasmic membranes (CM) from the stable Escherichia coli WF+ L-form on macrophage activity was also studied. It was established that rat macrophages more actively phagocytosed the plasmidless pYV(-) Y. enterocolitica cells, compared to the plasmid-bearing pYV(+) Y. enterocolitica cells. The killing ability against both variants of the Y. enterocolitica strain was significantly enhanced in macrophages from CM-treated rats after 2 h, 4 h, and 24 h incubation. The CM treatment enhanced the phagocytic activity of the macrophages. The in vitro interaction of normal and immunostimulated rat macrophages with both pYV(+) and pYV(-) variants of Y. enterocolitica did not lead to any additional apoptotic and necrotic changes in macrophages compared to control macrophages, which were cultivated without Y. enterocolitica. Electron-microscopic investigation showed that mouse macrophages eliminated Y. enterocolitica pYV(+) cells in vivo after 24 h. No engulfed or digested bacterial cells were observed. Activation of cell surfaces and vacuolization of macrophage cytoplasm, both of CM-treated non-infected and infected mice, were observed. The experimental results showed that Y. enterocolitica pYV(+) cells could be eliminated by peritoneal macrophages.     

Inhibition of yeast binding to mouse peritoneal macrophages by wheat germ agglutinin: a novel effect of the lectin on phagocytic cells

The ability of wheat germ agglutinin (WGA) to enhance the binding of bacteria and tumor cells to phagocytic cells, and to induce the killing of tumor cells by macrophages and monocytes, is well established. We observed, however, that WGA inhibits the binding to and phagocytosis of yeast cells by thioglycolate-elicited murine peritoneal macrophages. In order to follow these processes rapidly, the yeasts were labeled with Congo-red and their binding to the macrophages was measured spectrophotometrically after treatment with sodium dodecylsulfate. Phagocytosis was also followed by light microscopy. Binding of the yeasts was inhibited by about 80% after pretreating the macrophages with 150 micrograms/ml of WGA. This effect was reversed by subsequent incubation with N-acetyl-D-glucosamine, chitobiose or chitotriose, but was unaffected by methyl alpha-D-mannoside, N-acetyl-D-mannosamine, D-mannose or D-galactose. Pretreatment of the Congo-red yeasts with WGA did not inhibit their binding by the macrophages. Of a variety of lectins tested, only WGA and Datura stramonium lectin had this effect. Pretreating the macrophages with sialidase prevented the inhibition induced by WGA. Our findings suggest the presence on the macrophages of a class of WGA receptors not previously reported.     

The Use of Anchored Agonists of Phagocytic Receptors for Cancer Immunotherapy: B16-F10 Murine Melanoma Model

The application of the phagocytic receptor agonists in cancer immunotherapy was studied. Agonists (laminarin, molecules with terminal mannose, N-Formyl-methioninyl-leucyl-phenylalanine) were firmly anchored to the tumor cell surface. When particular agonists of phagocytic receptors were used together with LPS (Toll-like receptor agonist), high synergy causing tumour shrinkage and a temporary or permanent disappearance was observed. Methods of anchoring phagocytic receptor agonists (charge interactions, anchoring based on hydrophobic chains, covalent bonds) and various regimes of phagocytic agonist/LPS mixture applications were tested to achieve maximum therapeutic effect. Combinations of mannan/LPS and f-MLF/LPS (hydrophobic anchors) in appropriate (pulse) regimes resulted in an 80% and 60% recovery for mice, respectively. We propose that substantial synergy between agonists of phagocytic and Toll-like receptors (TLR) is based on two events. The TLR ligand induces early and massive inflammatory infiltration of tumors. The effect of this cell infiltrate is directed towards tumor cells, bearing agonists of phagocytic receptors on their surface. The result of these processes was effective killing of tumor cells. This novel approach represents exploitation of innate immunity mechanisms for treating cancer.     

Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma

In the current study, we examined the potential significance of CD44 expression on lymphokine-activated killer (LAK) cells in their interaction and killing of melanoma cells. Stimulation of splenocytes with IL-2 led to a significant increase in the expression of CD44 on T cells, NK cells, and NKT cells. Treatment of melanoma-bearing CD44 WT mice with IL-2 led to a significant reduction in the local tumor growth while treatment of melanoma-bearing CD44 KO mice with IL-2 was ineffective at controlling tumor growth. Furthermore, the ability of splenocytes from IL-2-treated CD44 KO mice to kill melanoma tumor targets was significantly reduced when compared to the anti-tumor activity of splenocytes from IL-2-treated CD44 WT mice. The importance of CD44 expression on the LAK cells was further confirmed by the observation that adoptively transferred CD44 WT LAK cells were significantly more effective than CD44 KO LAK cells at controlling tumor growth in vivo. Next, the significance of the increased expression of CD44 in tumor killing was examined and showed that following stimulation with IL-2, distinct populations of cells with low (CD44^lo) or elevated (CD44^hi) expression of CD44 are generated and that the CD44^hi cells are responsible for killing of the melanoma cells. The reduced killing activity of the CD44 KO LAK cells did not result from reduced activation or expression of effector molecules but was due, at least in part, to a reduced ability to adhere to B16F10 tumor cells.     

Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC

α active specific immunotherapy aims at stimulating the host's immune system to recognize and eradicate malignant cells. The concomitant activation of dendritic cells (DC) and natural killer (NK) cells is an attractive modality for immune-based therapies. Inducing immunogenic cell death to facilitate tumor cell recognition and phagocytosis by neighbouring immune cells is of utmost importance for guiding the outcome of the immune response. We previously reported that acute myeloid leukemic (AML) cells in response to electroporation with the synthetic dsRNA analogue poly(I:C) exert improved immunogenicity, demonstrated by enhanced DC-activating and NK cell interferon-γ-inducing capacities. To further invigorate the potential of these immunogenic tumor cells, we explored their effect on the phagocytic and cytotoxic capacity of DC and NK cells, respectively. Using single-cell analysis, we assessed these functionalities in two- and three-party cocultures. Following poly(I:C) electroporation AML cells become highly susceptible to NK cell-mediated killing and phagocytosis by DC. Moreover, the enhanced killing and the improved uptake are strongly correlated. Interestingly, tumor cell killing, but not phagocytosis, is further enhanced in three-party cocultures provided that these tumor cells were upfront electroporated with poly(I:C). Altogether, poly(I:C)-electroporated AML cells potently activate DC and NK cell functions and stimulate NK-DC cross-talk in terms of tumor cell killing. These data strongly support the use of poly(I:C) as a cancer vaccine component, providing a way to overcome immune evasion by leukemic cells.     

Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer

Lewis lung carcinoma (3LL) cells were constitutively resistant to Fas-mediated apoptosis, but overexpression of Fas on 3LL cells allowed Fas-mediated apoptosis after crosslinking with agonist anti-Fas antibody (Jo2) in vitro. Surprisingly, Fas-overexpressing 3LL cells showed enhanced in vivo tumor progression, whereas no promotion of in vivo tumor growth was observed for dominant negative (DN) Fas-overexpressing 3LL transfectants in which the cytoplasmic death domain was deleted. In addition, the promotion of in vivo tumor growth by Fas-overexpression was reduced in gld (FasL-mutation) mice compared to normal mice. These data indicate that intact Fas/FasL cell signaling is required for the promotion of in vivo tumor growth by Fas overexpression in 3LL cells. In contrast to the efficient Fas-mediated killing induced in vitro by crosslinking with anti-Fas antibody, Fas-overexpressing 3LL cells were resistant in vitro to Fas-mediated apoptosis by activated T cells or transient FasL transfection. These data suggest that agonist anti-Fas antibody and natural FasL can transmit qualitatively different signals, and crosslinking of Fas with natural FasL on 3LL cells does not deliver the expected death signal. Thus, our results demonstrate that in some cases overexpression of Fas can result in a survival advantage for tumor cells in vivo.     

Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells

Transfection of tumor cells with a vector containing the entire coding sequence of human interleukin-2 (hIL-2) was previously shown to convert the tumorigenic murine fibrosarcoma line CMS-5 into a non-tumorigenic line. The failure of the IL-2-secreting tumor to grow in conventional (immunocompetent) mice was attributed to the activation of CD8⁺ T cells that exhibited tumor specificity and memory. In order to determine whether or not the IL-2 produced by the tumor may be activating tumor cytotoxic effector cells other than B or T cells we have repeated this study using immunodeficient SCID and SCID-beige mice as syngeneic tumor recipients. In contrast to the rapid growth of the wild-type tumor, the hIL-2-transfected cells (N2A/IL2/CMS5) did not grow, or grew more slowly and regressed, in the mice that lack functional B and T cells. The inhibition of tumor growth associated with the local release of IL-2 was reversed in mice treated with antiasialo-GM1 antibodies specific for natural killer (NK) lineage cells. In contrast to the studies with conventional mice, the IL-2-dependent effector cells in the immunodeficient mice exhibited no evidence of memory. In vitro analysis of spleen cells from tumor-bearing mice revealed the presence of effector cells able to lyse YAC-1 target cells as well as the wild-type CMS-5 and the IL-2-transfected variant tumor lines but unable to lyse P815 cells. The pattern of selective target cell killing and the kinetics of killing were indistinguishable from those observed using tumor necrosis factor (TNF) the mediator associated with natural cytotoxicity cell killing of tumor cells. Histopathology of the IL-2-secreting tumors in SCID mice reveals the presence of infiltrating lymphoid cells and macrophages that were not observed in the CMS-5 tumors. Consistent with the notion that the tumor killing in the SCID mice was mediated by TNF, mice bearing IL-2-secreting tumors had elevated levels of serum TNF and little or no effector cell activity, or TNF was found in tumor-bearing mice treated with anti-asialo-GM1 antibody. The results indicate that the cytokine-induced tumor regression observed in the IL-2-transfected tumors is a more complex phenomenon than previously recognized and one that is mediated by effector cells of the NK cell and/or monocyte/macrophage lineages, in addition to CD8⁺ T cells.This investigation was supported by awards from Department of Health and Human Services, Public Health Service: CA09 581 (TA), CA25 253, CA54 491, CA57 974 and CA22 786 (RBB), and Natural Sciences and Engineering Council, Canada (BAC)     

双歧杆菌脂磷壁酸对B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响

目的探讨双歧杆菌脂磷壁酸（LTA）对黑色素瘤B16荷瘤小鼠NK细胞受体NKG2D及其配体的影响。方法将黑色素瘤B16细胞接种于C57BL／6小鼠皮下,待触及肿块后于荷瘤小鼠皮下注射双歧杆菌LTA。采用MTT、流式细胞术（FCM）、RT-PCR方法分别检测经双歧杆菌LTA处理后B16荷瘤小鼠NK细胞杀伤活性、NK细胞NKG2D受体蛋白表达以及肿瘤组织内Rae-1、H60 mRNA表达的变化。结果与对照组相比,经双歧杆菌LTA处理后,B16荷瘤小鼠的NK细胞杀伤活性增强（P〈0．05）,NK细胞受体NKG2D表达明显增加（P〈0．05）,肿瘤组织Rae-1、H60 mRNA表达上升（P〈0．05）,并具有浓度依赖性。结论双歧杆菌LTA能够增强B16荷瘤小鼠NK细胞的杀伤活性,其机制可能与上调NK细胞受体NKG2D的蛋白表达和肿瘤组织Rae-1、H60 mRNA的表达有关。